Approved comparison material connected to this topic.
3 total recordsSource comparisons are presented without a generated winner.
PT-141 (Bremelanotide) MC3R/MC4R melanocortin receptor agonist in hypothalamus. Central arousal pathway activation Phase 3 RCT (n=1,267) showed 52% response rate vs 32% placebo for HSDD in premenopausal women;…
PT-141 (Bremelanotide) MC4R agonist. Increases dopamine, reduces GABAergic inhibition of arousal Phase III trials in HSDD; statistically significant improvement in desire and arousal scores 1.75mg subcutaneous…
PT-141 (Bremelanotide) MC4R agonist. Increases dopamine/NE in arousal centres Phase 3 RCTs, FDA-approved for female HSDD Subcutaneous injection 45–90 minutes Approved (Vyleesi) Transient nausea in 40% of users…